Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation

Aims: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to treat non-small cell lung cancer (NSCLC) patients with EGFR mutation, but TKI resistance is common. Almost half of the acquired resistance patients are due to additional T790M mutation on EGFR (EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Elaine Lai-Han, Fan, Xing-Xing, Wong, Maria Pik, Jiang, Zhi-Hong, Liu, Zhong-Qiu, Yao, Xiao-Jun, Lu, Lin-Lin, Zhou, Yan-Ling, Yau, Li-Fong, Tin, Vicky Pui-Chi, Liu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2016
Materias:
Original Research Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753639/
https://www.ncbi.nlm.nih.gov/pubmed/26528827
http://dx.doi.org/10.1089/ars.2015.6420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753639/
https://www.ncbi.nlm.nih.gov/pubmed/26528827
http://dx.doi.org/10.1089/ars.2015.6420

Ejemplares similares